Idexx Laboratories

Idexx Laboratories, a US-based Pharmaceutical Preparation Manufacturing company, has established a near-term absolute target to reduce its Scope 1 and 2 greenhouse gas (GHG) emissions by 37.8% by 2030, compared to a 2021 baseline.

In terms of emissions data, for the 2025 reporting year, Idexx Laboratories reported Scope 2 emissions from purchased electricity amounting to approximately 19.17 million kg CO2e. For the 2024 reporting year, Scope 2 emissions from purchased electricity were approximately 20.24 million kg CO2e. In 2023, Scope 2 emissions from purchased electricity totalled approximately 18.56 million kg CO2e.

For the 2022 reporting year, Scope 1 emissions were approximately 16.14 million kg CO2e, and Scope 2 emissions were approximately 18.01 million kg CO2e, bringing the combined Scope 1 and 2 total to approximately 34.15 million kg CO2e. In 2021, Scope 1 emissions were approximately 16.65 million kg CO2e and Scope 2 emissions were approximately 17.38 million kg CO2e, with a combined Scope 1 and 2 total of approximately 34.03 million kg CO2e.

Previous years show:

• 2020: Scope 1 emissions were approximately 13.50 million kg CO2e, and Scope 2 emissions were approximately 16.59 million kg CO2e, for a combined Scope 1 and 2 total of approximately 30.09 million kg CO2e.
• 2019: Scope 1 emissions were approximately 17.35 million kg CO2e, and Scope 2 emissions were approximately 19.81 million kg CO2e, with a combined Scope 1 and 2 total of approximately 37.15 million kg CO2e.
• 2017: Scope 1 and 2 emissions combined totalled approximately 21.16 million kg CO2e.

Idexx Laboratories' emissions reporting currently focuses on Scope 1 and Scope 2, with Scope 3 data, specifically purchased goods and services, being